BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 27311868)

  • 1. Aberrant differential expression of EZH1 and EZH2 in Polycomb repressive complex 2 among B- and T/NK-cell neoplasms.
    Abdalkader L; Oka T; Takata K; Sato H; Murakami I; Otte AP; Yoshino T
    Pathology; 2016 Aug; 48(5):467-82. PubMed ID: 27311868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In aggressive variants of non-Hodgkin lymphomas, Ezh2 is strongly expressed and polycomb repressive complex PRC1.4 dominates over PRC1.2.
    Abd Al Kader L; Oka T; Takata K; Sun X; Sato H; Murakami I; Toji T; Manabe A; Kimura H; Yoshino T
    Virchows Arch; 2013 Nov; 463(5):697-711. PubMed ID: 23948956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of the polycomb repressive complex pathway in T and NK cell lymphoma: biological and prognostic implications.
    Kim SH; Yang WI; Min YH; Ko YH; Yoon SO
    Tumour Biol; 2016 Feb; 37(2):2037-47. PubMed ID: 26337274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ezh1 and Ezh2 differentially regulate PSD-95 gene transcription in developing hippocampal neurons.
    Henriquez B; Bustos FJ; Aguilar R; Becerra A; Simon F; Montecino M; van Zundert B
    Mol Cell Neurosci; 2013 Nov; 57():130-43. PubMed ID: 23932971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer.
    Wassef M; Luscan A; Aflaki S; Zielinski D; Jansen PWTC; Baymaz HI; Battistella A; Kersouani C; Servant N; Wallace MR; Romero P; Kosmider O; Just PA; Hivelin M; Jacques S; Vincent-Salomon A; Vermeulen M; Vidaud M; Pasmant E; Margueron R
    Proc Natl Acad Sci U S A; 2019 Mar; 116(13):6075-6080. PubMed ID: 30867289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer.
    Liu YL; Gao X; Jiang Y; Zhang G; Sun ZC; Cui BB; Yang YM
    J Cancer Res Clin Oncol; 2015 Apr; 141(4):661-9. PubMed ID: 25326896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The competitive mechanism of EZH1 and EZH2 in promoting oral squamous cell carcinoma.
    Chen J; Tang S; Zheng Q; Li J; Jiang H; Lu H; Liao G; Li K; Liang Y
    Exp Cell Res; 2024 Mar; 436(1):113957. PubMed ID: 38309675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polycomb Repressive Complex 2 Proteins EZH1 and EZH2 Regulate Timing of Postnatal Hepatocyte Maturation and Fibrosis by Repressing Genes With Euchromatic Promoters in Mice.
    Grindheim JM; Nicetto D; Donahue G; Zaret KS
    Gastroenterology; 2019 May; 156(6):1834-1848. PubMed ID: 30689973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancer of zeste homolog 2 is widely expressed in T-cell neoplasms, is associated with high proliferation rate and correlates with MYC and pSTAT3 expression in a subset of cases.
    Shi M; Shahsafaei A; Liu C; Yu H; Dorfman DM
    Leuk Lymphoma; 2015 Jul; 56(7):2087-91. PubMed ID: 25263318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma.
    Visser HP; Gunster MJ; Kluin-Nelemans HC; Manders EM; Raaphorst FM; Meijer CJ; Willemze R; Otte AP
    Br J Haematol; 2001 Mar; 112(4):950-8. PubMed ID: 11298590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High expression of Polycomb group protein EZH2 predicts poor survival in salivary gland adenoid cystic carcinoma.
    Vékony H; Raaphorst FM; Otte AP; van Lohuizen M; Leemans CR; van der Waal I; Bloemena E
    J Clin Pathol; 2008 Jun; 61(6):744-9. PubMed ID: 18326020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developmental control of polycomb subunit composition by GATA factors mediates a switch to non-canonical functions.
    Xu J; Shao Z; Li D; Xie H; Kim W; Huang J; Taylor JE; Pinello L; Glass K; Jaffe JD; Yuan GC; Orkin SH
    Mol Cell; 2015 Jan; 57(2):304-316. PubMed ID: 25578878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EZH2 expression is associated with inferior overall survival in mantle cell lymphoma.
    Martinez-Baquero D; Sakhdari A; Mo H; Kim DH; Kanagal-Shamanna R; Li S; Young KH; O'Malley DP; Dogan A; Jain P; Wang ML; McDonnell TJ; Miranda RN; Vega F; Medeiros LJ; Ok CY
    Mod Pathol; 2021 Dec; 34(12):2183-2191. PubMed ID: 34376807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors.
    Yang X; Li F; Konze KD; Meslamani J; Ma A; Brown PJ; Zhou MM; Arrowsmith CH; Kaniskan HÜ; Vedadi M; Jin J
    J Med Chem; 2016 Aug; 59(16):7617-33. PubMed ID: 27468126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer.
    Lee H; Yoon SO; Jeong WY; Kim HK; Kim A; Kim BH
    Hum Pathol; 2012 Oct; 43(10):1704-10. PubMed ID: 22520951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential expression of enhancer of zeste homolog 2 (EZH2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 expression by p-ERK1/2 and MYC in aggressive B-cell lymphomas.
    Tian X; Pelton A; Shahsafaei A; Dorfman DM
    Mod Pathol; 2016 Sep; 29(9):1050-7. PubMed ID: 27282353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas.
    Yamagishi M; Hori M; Fujikawa D; Ohsugi T; Honma D; Adachi N; Katano H; Hishima T; Kobayashi S; Nakano K; Nakashima M; Iwanaga M; Utsunomiya A; Tanaka Y; Okada S; Tsukasaki K; Tobinai K; Araki K; Watanabe T; Uchimaru K
    Cell Rep; 2019 Nov; 29(8):2321-2337.e7. PubMed ID: 31747604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polycomb repressive complex 2 (PRC2) suppresses Eμ-myc lymphoma.
    Lee SC; Phipson B; Hyland CD; Leong HS; Allan RS; Lun A; Hilton DJ; Nutt SL; Blewitt ME; Smyth GK; Alexander WS; Majewski IJ
    Blood; 2013 Oct; 122(15):2654-63. PubMed ID: 23982173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of Combined EZH2, p-ERK1/2, p-STAT, and MYC Expression in the Differential Diagnosis of EZH2-positive Hodgkin Lymphomas and Related Large B-Cell Lymphomas.
    Tian X; Xu J; Dorfman DM
    Am J Surg Pathol; 2019 Jan; 43(1):102-109. PubMed ID: 30371509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of polycomb repressive complex 2 key components EZH2/SUZ12/EED as an unfavorable prognostic marker in cholangiocarcinoma.
    Wasenang W; Puapairoj A; Settasatian C; Proungvitaya S; Limpaiboon T
    Pathol Res Pract; 2019 Jul; 215(7):152451. PubMed ID: 31126817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.